What an Efflux Pump Is and Its Role in Drug Resistance

An efflux pump is a protein embedded in a cell’s membrane that actively pushes toxic substances, including drugs, out of the cell before they can do their damage. Bacteria, fungi, and even human cancer cells use these molecular bouncers to survive exposure to medications that would otherwise kill them. Because many efflux pumps can expel a wide range of structurally unrelated compounds, a single pump can make a cell resistant to multiple drugs at once, a phenomenon called multidrug resistance. Understanding how these pumps work is central to figuring out why some infections and cancers stop responding to treatment.

How Efflux Pumps Move Drugs Out

Efflux pumps are not all powered the same way. Some are driven by the proton motive force, the natural electrochemical gradient that exists across a bacterial membrane. These pumps essentially trade a proton (a hydrogen ion) flowing inward for a drug molecule being shoved outward. Others run on ATP, the universal energy currency of the cell, directly burning fuel to push drugs out. Research in the bacterium Lactococcus lactis demonstrated both systems operating side by side: one efflux system for ethidium bromide collapsed when the proton gradient was disrupted, while a different efflux system in a resistant strain was blocked by an ATP-pathway inhibitor instead.¹ The practical takeaway is that a bacterium does not rely on just one exit strategy. It can have several pumps, each with its own fuel source, running at the same time.

In Gram-negative bacteria, the engineering problem is even more impressive. These organisms have two concentric membranes with a gap (the periplasm) between them. Simply pushing a drug out of the inner membrane would leave it stranded in that gap, free to leak back in. So certain pumps assemble into tripartite complexes: an inner-membrane transporter, a periplasmic adaptor protein, and an outer-membrane channel, all linked together to form a continuous tunnel that ejects drugs completely out of the cell.² It is a remarkably elegant piece of molecular plumbing.

The Major Efflux Pump Families

Efflux pumps are grouped into superfamilies based on their structure and energy source. Knowing the family matters because different families dominate in different organisms and respond differently to potential inhibitors. The main ones you will see referenced are:

• Major Facilitator Superfamily (MFS): The largest and most diverse group, found in bacteria and fungi alike. MFS pumps are secondary active transporters, driven by ion gradients rather than ATP. They typically have 12 or 14 membrane-spanning segments and can transport an enormous range of substrates, from antibiotics and dyes to sugars and amino acids.³
• Resistance-Nodulation-Division (RND): The heavy hitters in Gram-negative bacteria. These form the tripartite assemblies described above and are proton-driven. The well-studied AcrAB-TolC system in E. coli and MexAB-OprM in Pseudomonas aeruginosa belong to this family.
• ATP-Binding Cassette (ABC): ATP-powered pumps found across all domains of life. In humans, ABC transporters like P-glycoprotein are responsible for pumping chemotherapy drugs out of cancer cells.
• Small Multidrug Resistance (SMR): Compact, proton-driven pumps often carried on mobile genetic elements, making them easy to spread between bacteria.
• Multidrug and Toxic Compound Extrusion (MATE): Ion-gradient-driven pumps found in both bacteria and eukaryotes.

Most bacteria carry genes for pumps from several of these families, giving them overlapping layers of protection. In Staphylococcus aureus, for example, both chromosomal and plasmid-encoded efflux pumps from multiple families contribute to resistance against different classes of antimicrobial agents.⁴ Research into inhibitors for Gram-positive bacteria has focused heavily on the NorA pump (an MFS transporter) in S. aureus, though experts have argued that the field needs to broaden its attention to other pump families as well.⁵

What Efflux Pumps Were Actually Built For

One common misconception is that bacteria evolved efflux pumps specifically to defeat human-made antibiotics. The reality is more nuanced. Many of these pumps are ancient, conserved across species that diverged long before the antibiotic era, which strongly suggests they originally served housekeeping roles unrelated to drug resistance.⁶ Their ability to expel antibiotics may be a lucky accident, from the bacterium’s perspective, that turned out to be incredibly useful once humans started flooding environments with antimicrobial drugs.

So what were these pumps doing before antibiotics came along? Some remove toxic metabolic byproducts that the bacterium generates internally. In Pseudomonas aeruginosa, the MexGHI-OpmD pump appears to export anthranilate, a toxic intermediate the bacterium produces during cell-to-cell signaling.⁷ Others protect bacteria from hostile chemicals in their natural habitats. E. coli, which lives in the gut, uses the AcrAB system to pump out bile salts, the detergent-like molecules that the liver produces to digest fats. Without active bile salt efflux, E. coli accumulates these compounds and its growth is severely inhibited.⁸

The fact that efflux pumps were shaped by millions of years of environmental pressure, not by decades of antibiotic use, helps explain why they are so widespread and so hard to eliminate. You cannot simply knock them out without affecting the bacterium’s ability to survive its natural environment.

The Double Barrier in Gram-Negative Bacteria

Efflux pumps do not work in isolation. In Gram-negative bacteria, they cooperate with the outer membrane to create a defense that is greater than the sum of its parts. The outer membrane acts as a passive sieve, slowing the entry of many antibiotics. Efflux pumps then actively remove whatever manages to seep through. Experimental work has shown that the intracellular concentration of antibiotics in these bacteria is governed by a synergistic relationship between efflux activity and membrane permeability, not by either factor alone.⁹

What makes this synergy so formidable is that the outer membrane and the efflux pumps select against drugs based on different physical properties. The outer membrane tends to block large, hydrophobic molecules, while efflux pumps preferentially eject compounds based on charge, shape, or other characteristics. Together, they create a filter-and-flush system that dramatically reduces the intracellular accumulation of a wide range of structurally diverse antibiotics.¹⁰ This is a major reason why Gram-negative infections are generally harder to treat than Gram-positive ones, and why developing new antibiotics against organisms like Pseudomonas and Klebsiella is so challenging.

How Bacteria Crank Up Their Pumps

Most bacteria carry efflux pump genes on their chromosomes as standard equipment, but those genes are not always cranked up to full production. Under normal conditions, repressor proteins keep pump expression at low, baseline levels. Resistance emerges when something breaks or changes that control system. There are several routes to overproduction: mutations in the gene encoding a local repressor, mutations in a broader regulatory gene that controls many genes at once, changes in the promoter region that controls how often the pump gene is read, or the insertion of mobile genetic elements that override normal regulation.¹¹

A well-studied example involves Campylobacter jejuni, a common cause of foodborne illness. The CmeR protein normally acts as a brake on the CmeABC efflux pump. When researchers disrupted CmeR, the pump was overproduced. Even a single nucleotide deletion in the regulatory region was enough to weaken CmeR’s grip and ramp up efflux pump output.¹² The ease with which these regulatory switches can flip is sobering. Bacteria do not need to acquire foreign resistance genes from other organisms. A single random mutation in their own DNA can be enough to unleash much higher pump activity.

Beyond Drug Resistance: Biofilms and Virulence

Efflux pumps do more than just eject antibiotics. Growing evidence ties them to biofilm formation, the process by which bacteria stick to surfaces and encase themselves in a protective slime layer. Biofilms are clinically significant because bacteria living within them are far harder to kill with antibiotics or immune responses than free-floating cells. Studies across several major pathogens, including E. coli, Pseudomonas aeruginosa, Acinetobacter baumannii, and Staphylococcus aureus, have found that knocking out specific efflux pump genes or adding efflux pump inhibitors reduces biofilm formation.¹³

Efflux pumps also contribute to virulence more broadly. They help pathogens expel toxic compounds produced by the host immune system, such as antimicrobial peptides and reactive oxygen species, allowing bacteria to survive in hostile tissue environments and establish persistent infections.¹⁴ This dual role means that an effective efflux pump inhibitor might not only restore antibiotic susceptibility but also weaken the bacterium’s ability to cause disease in the first place.

Efflux Pumps in Fungi and Cancer

Bacteria are not the only organisms that use efflux to dodge drugs. Fungal pathogens employ the same strategy against antifungal medications. In species like Candida albicans and Candida glabrata, resistance to azole antifungals, the most commonly prescribed class, frequently involves overexpression of ABC and MFS transporters on the cell membrane.¹⁵ Researchers have found that certain compounds, including the monoamine oxidase inhibitor clorgyline, can block both ABC and MFS efflux in Candida species and reverse azole resistance in laboratory settings.¹⁶

In human cancer, the same fundamental mechanism undermines chemotherapy. The best-known player is P-glycoprotein (also called ABCB1), an ABC transporter that sits on the surface of cancer cells and pumps a wide range of chemotherapy drugs back out before they reach lethal concentrations inside the cell.¹⁷ P-glycoprotein is not the only one. Other ABC family members, including breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (MRPs), also actively efflux chemotherapy agents and reduce their effectiveness.¹⁸ The challenge is that P-glycoprotein and its relatives also perform important protective functions in healthy tissues, particularly at the blood-brain barrier and in the gut and kidneys, where they help keep toxins out. Blocking them systemically risks serious side effects.

Detecting Efflux Pump Activity

Before you can address efflux-mediated resistance, you need to know it is there. One widely used laboratory method involves ethidium bromide, a fluorescent dye that glows brightly when it accumulates inside cells but dims when it is pumped out. Researchers load bacterial cells with ethidium bromide under conditions where efflux is suppressed (low temperature, no energy source) and then watch what happens when they restore normal conditions. Cells with active efflux pumps rapidly expel the dye, causing fluorescence to drop. Adding an efflux pump inhibitor like chlorpromazine blocks this expulsion and keeps fluorescence high.¹⁹

Another approach is simpler: measuring the minimum inhibitory concentration (MIC) of ethidium bromide for clinical isolates. A study of over 300 S. aureus clinical strains found that roughly half had increased expression of one or more efflux pump genes. The ethidium bromide MIC test was highly specific at identifying strains that were actively effluxing, correctly flagging them about 99% of the time, though it was less sensitive at catching strains that had upregulated pump genes without yet showing strong efflux activity.²⁰ The ethidium bromide assay has also been adapted to work with mixed environmental samples, extending its usefulness beyond pure laboratory cultures.²¹

The Search for Efflux Pump Inhibitors

If efflux pumps are a major driver of drug resistance, the obvious therapeutic strategy is to block them. Pair an antibiotic with an efflux pump inhibitor, and you could potentially restore the antibiotic’s effectiveness against resistant bacteria. Researchers have been pursuing this idea for decades, and some promising candidates have emerged.

One recent example is BDM91288, a synthetic compound designed to inhibit the AcrB pump in Klebsiella pneumoniae. In laboratory tests, BDM91288 boosted the activity of a panel of antibiotics against K. pneumoniae and reversed resistance caused by overexpression of the AcrAB-TolC efflux system. Structural studies confirmed the compound binds directly to the pump’s transmembrane region.²² Another candidate, a naturally derived compound called RP1, inhibits RND-type pumps in both E. coli and Pseudomonas aeruginosa, working synergistically with existing antibiotics to lower the concentration needed to stop bacterial growth.²³

Plant-derived compounds have also attracted attention. Polyphenols like curcumin, quercetin, and epigallocatechin-3-gallate (the compound famous in green tea) have shown the ability to inhibit efflux pumps, either by physically interfering with pump proteins or by dialing down expression of the genes that encode them. Some of these polyphenols work synergistically with antibiotics such as ciprofloxacin, tetracycline, and colistin, and quercetin in particular has demonstrated inhibitory potency comparable to established laboratory pump inhibitors like verapamil and reserpine.²⁴ Broader surveys have identified promising efflux pump inhibitory activity in phytochemicals from plant families including Berberidaceae, Lamiaceae, and Zingiberaceae, among others.²⁵

Despite all this laboratory success, no efflux pump inhibitor has yet made it into clinical use. The reasons are frustratingly practical: formulation difficulties, toxicity in animal models, poor pharmacokinetics (the drug does not get to the right place in the body at the right concentration for long enough), and sometimes too narrow a spectrum of activity to justify the added complexity of a combination therapy.²⁶ Blocking a pump in a test tube is one thing. Doing it safely inside a human body, where the same or related pumps protect healthy cells, is a far harder problem.

Collateral Sensitivity as a Potential Exploit

One of the more intriguing recent angles in efflux pump research involves collateral sensitivity: the idea that becoming resistant to one thing can make an organism more vulnerable to something else. When a bacterium upregulates a particular efflux pump to resist one class of antibiotics, it sometimes becomes more susceptible to a different class. In Pseudomonas aeruginosa, mutations that overproduce the MexCD-OprJ pump (leading to resistance against certain drugs) also create collateral sensitivity to aminoglycosides, beta-lactams, and colistin.²⁷

The trade-offs can extend beyond antibiotics entirely. A preprint studying Caulobacter vibrioides found that a mutant constitutively overproducing an RND efflux pump showed heightened sensitivity to copper, zinc, nickel, and cadmium. The researchers attributed this vulnerability to the energetic burden of running efflux at full blast, which apparently left the cell less able to cope with metal stress.²⁸ If these findings hold up, they point toward therapeutic strategies that exploit resistance rather than simply trying to overcome it: cycling or combining drugs in a way that uses the bacterium’s own resistance mechanism against it. The research is still in its early stages, but collateral sensitivity represents a genuinely different way of thinking about the arms race between drugs and efflux pumps.